Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.
N-Acetylcysteine Protects Against Acute Renal Insult in Patients With Abnormal Renal Function Undergoing Cardiopulmonary Bypass.
Sponsor: Far Eastern Memorial Hospital
Listed as NCT00190034, this PHASE4 trial focuses on Cardiopulmonary Bypass and Cardiovascular Disease and remains suspended. Sponsored by Far Eastern Memorial Hospital, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Suspended PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Suspended PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Suspended PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Suspended PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Suspended PHASE4
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Far Eastern Memorial Hospital
- Synmosa Biopharma Corp.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Banqiao District, Taiwan